<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00849147</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN0603</org_study_id>
    <secondary_id>U01HL069294</secondary_id>
    <secondary_id>5U24CA076518</secondary_id>
    <nct_id>NCT00849147</nct_id>
  </id_info>
  <brief_title>Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)</brief_title>
  <official_title>A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bone marrow transplants are one treatment option for people with leukemia or lymphoma. Family
      members or unrelated donors with a similar type of bone marrow usually donate their bone
      marrow to the transplant patients. This study will evaluate the effectiveness of a new type
      of bone marrow transplant—one that uses lower doses of chemotherapy and bone marrow donated
      from family members with only partially matched bone marrow—in people with leukemia or
      lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Leukemia and lymphoma are types of blood cancers. Chemotherapy is a common treatment option
      for people with these types of cancers, but if the cancer does not respond well to
      chemotherapy, or if the cancer returns, a bone marrow transplant is another treatment option.
      In a bone marrow transplant procedure, healthy bone marrow is taken from a donor and
      transplanted into the patient. Bone marrow can be donated by a family member or an unrelated
      donor who has a similar type of bone marrow. Most bone marrow transplants are performed using
      a donor who is a perfect or close-to-perfect tissue match. However, for participants in this
      study, researchers have determined that a completely matched donor is unavailable within
      participants' families, and an unrelated donor match has not been found either. Participants
      do, however, have a family member who is a partial tissue match. Typically, people who are
      undergoing a bone marrow transplant receive high doses of chemotherapy before the transplant
      to prepare their bodies to accept the donor bone marrow. In this study, participants will
      undergo a new type of bone marrow transplant called a nonmyeloablative transplant, which is a
      reduced intensity method of transplantation that does not require high doses of chemotherapy.
      The purpose of the study is to examine the safety and effectiveness of a nonmyeloablative
      bone marrow transplant that uses partially matched bone marrow donated by a family member as
      a treatment option for people with leukemia or lymphoma.

      This study will enroll people with leukemia or lymphoma who have a family member with a
      partial tissue match. Participants will be admitted to the hospital and will first receive a
      type of chemotherapy called fludarabine, which will be given intravenously for 5 days. In
      addition, another type of chemotherapy, cyclophosphamide, will be given intravenously on the
      first and second day. After 5 days, participants will receive a small dose of radiation. The
      next day, participants will undergo the bone marrow transplant. The third and fourth day
      after the transplant, participants will receive high doses of cyclophosphamide to help
      prevent two complications, graft rejection, which occurs when the body's immune system
      rejects the donor bone marrow, and graft-versus-host disease (GVHD), which is an attack by
      the donor cells on the body's normal tissues. On the fifth day after the transplant,
      participants will receive two additional medications, tacrolimus and mycophenolate mofetil
      (MMF), to help prevent GVHD; some participants may receive cyclosporine instead of
      tacrolimus. Participants will receive MMF for about 5 weeks and tacrolimus for about 6
      months. Also beginning on the fifth day after the transplant, participants will receive daily
      injections of a growth factor called granulocyte-colony stimulating factor (G-CSF), which is
      a natural protein that increases the white blood cell count; G-CSF will be continued until a
      participant's white blood cell count is normal again.

      Participants will remain in the hospital for approximately 2 to 3 months, but possibly longer
      if there are complications. While participants are in the hospital, blood samples will be
      collected regularly to evaluate the response and possible side effects to treatment,
      including GVHD. If necessary, participants will receive platelet and red blood cell
      transfusions. Follow-up study visits will occur 6 months and 1 year after the transplant. At
      Months 1, 2, 6, and 12 after the transplant, blood or bone marrow samples will be obtained.
      Study researchers will keep track of participants' medical condition through phone calls or
      mailings to participants and their doctors once a year for the rest of the participants'
      lives.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival at 180 Days From the Time of Transplant</measure>
    <time_frame>Measured at Month 6 and Year 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutrophil Recovery</measure>
    <time_frame>Measured at Days 28, 56, 90, and 100</time_frame>
    <description>Cumulative incidence of neutrophil recovery &gt;500/μL at day +56</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Graft Failure</measure>
    <time_frame>Measured at Day 67</time_frame>
    <description>Primary graft failure is defined as &lt; 5% donor chimerism on all measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Graft Failure</measure>
    <time_frame>Measured at Day 100</time_frame>
    <description>Secondary graft failure is defined as initial recovery followed by neutropenia with &lt; 5% donor chimerism. If no chimerism assays were performed and absolute neutrophil count is &lt; 500/mm3, then it will be counted as a secondary graft failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Recovery</measure>
    <time_frame>Measured at Days 56, 90, and 100</time_frame>
    <description>Platelet Recovery to 20K</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Recovery</measure>
    <time_frame>Measured at Days 56, 90, and 100</time_frame>
    <description>Platelet Recovery to 50K</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Cell Engraftment</measure>
    <time_frame>Measured at Day 56</time_frame>
    <description>Marrow or Blood Sample. Donor cell engraftment is defined as donor chimerism ≥ 5% on Day ≥ 56 after transplantation. Chimerism should be evaluated on Days ~28, ~56, ~180, and ~365 after transplantation. Chimerism may be evaluated in whole blood or mononuclear fraction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Graft-versus-host Disease (GVHD)</measure>
    <time_frame>Measured at Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GVHD</measure>
    <time_frame>Measured at Year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Measured at Year 1</time_frame>
    <description>Progression-free survival is defined as the minimum time interval of the times to relapse/recurrence, to death or to last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related Mortality (TRM)</measure>
    <time_frame>Measured at 6 months and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>Measured at Year 1</time_frame>
    <description>Number of infections; infections will be reported by anatomic site, date of onset, organism and resolution, if any. Patients will be followed for infection for 1 year post-transplant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma</condition>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Burkitt Lymphoma</condition>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Lymphoma, Follicular</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <arm_group>
    <arm_group_label>Haploidentical Bone Marrow Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a human leucocyte antigen (HLA) haploidentical bone marrow transplantation using a non-myeloablative preparative regimen, GVHD prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Haploidentical Bone Marrow Transplantation</intervention_name>
    <description>The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.
Fludarabine: 30 mg/m2 intravenously (IV) on Days -6, -5, -4, -3, and -2
Cyclophosphamide (Cy): 14.5 mg/kg IV on Days -6 and -5
Total body irradiation (TBI): 200 centigray (cGy) on Day -1
Day 0 is the day of the infusion of non-T-cell depleted bone marrow. The bone marrow will be obtained from haploidentical related donor.</description>
    <arm_group_label>Haploidentical Bone Marrow Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GVHD prophylaxis</intervention_name>
    <description>The GVHD prophylaxis regimen will consist of the following:
Cy: 50 mg/kg IV on Days 3 and 4
Tacrolimus: (IV or orally) beginning on Day 5 with dose adjusted to maintain a level of 5 to 15 mg/mL
Mycophenolate mofetil (MMF): 15 mg/kg orally three times a day (TID) beginning on Day 5; maximum dose will be 1 g orally TID
Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg/day beginning on Day 5 until absolute neutrophil count (ANC) is greater than or equal to 1,000/mm^3 for 3 consecutive days</description>
    <arm_group_label>Haploidentical Bone Marrow Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must be 21 to 70 years old; participants 1 to 21 years old are also
             eligible if they are ineligible for BMT CTN #0501 (NCT00412360)

          -  Donor must be at least 18 years of age

          -  Human leucocyte antigen (HLA) typing will be performed at high resolution (allele
             level) for the HLA-A, -B, Cw, DRB1, and -DQB1 loci. A minimum match of 5/10 is
             required. An unrelated donor search is not required for a person to be eligible for
             this study if the clinical situation dictates an urgent transplant. Clinical urgency
             is defined as 6 to 8 weeks from referral to transplant center or low likelihood of
             finding a matched, unrelated donor. The donor and recipient must be identical, as
             determined by high resolution typing, on at least one allele of each of the following
             genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1. Fulfillment of this
             criterion shall be considered sufficient evidence that the donor and recipient share
             one HLA haplotype, and typing of additional family members is not required.

          -  Must have received cytotoxic chemotherapy within 3 months of the consent date
             (measured from the start date of chemotherapy)

          -  Acute leukemias (includes T lymphoblastic lymphoma) in the second or subsequent
             complete remission (CR)

          -  Burkitt's lymphoma in the second or subsequent CR

          -  Lymphoma

          -  Patients with adequate physical function as measured by the following:

               1. Heart: left ventricular ejection fraction at rest must be greater than or equal
                  to 35%, or shortening fraction greater than 25%

               2. Liver: bilirubin less than or equal to 2.5 mg/dL and alanine aminotransferase
                  (ALT), aspartate aminotransferase (AST), and alkaline phosphatase less than five
                  times the upper limit of normal

               3. Kidney: serum creatinine within normal range for age, or if serum creatinine is
                  outside the normal range for age, then kidney function (creatinine clearance or
                  glomerular filtration rate (GFR) is greater than 40 mL/min/1.73m^2

               4. Pulmonary: forced expiratory volume in one second (FEV1), forced vital capacity
                  (FVC), and carbon monoxide diffusing capacity (DLCO) greater than 50% predicted
                  (corrected for hemoglobin). If unable to perform pulmonary function tests, then
                  oxygen (O2) saturation must be greater than 92% on room air.

               5. Performance status: Karnofsky/Lansky score greater than or equal to 60%

        Exclusion Criteria:

          -  Have an HLA-matched, related, or 7 or 8/8 allele matched (HLA-A, -B, -Cw, -DRB1)
             related donor able to donate

          -  Had an autologous hematopoietic stem cell transplant in the 3 months before study
             entry

          -  Pregnant or breastfeeding

          -  Evidence of HIV infection or known HIV positive serology

          -  Current uncontrolled bacterial, viral, or fungal infection (i.e., currently taking
             medication with evidence of progression of clinical symptoms or radiologic findings)

          -  Prior allogeneic hematopoietic stem cell transplant

          -  History of primary idiopathic myelofibrosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Horowitz, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine (Shands)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bone Marrow Transplant Group of Georgia, Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kapi'olani Medical Center for Women and Children, University of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Greenbaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center (SKCCC)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DFCI, Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute, Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University, Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase, Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2442</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-8210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmtctn.net</url>
    <description>Click here for the Blood and Marrow Transplant (BMT) Clinical Trials Network (CTN) Web site</description>
  </link>
  <link>
    <url>https://bethematch.org/</url>
    <description>National Marrow Donor Program</description>
  </link>
  <results_reference>
    <citation>Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, Jagasia MH, Ballen KK, Eapen M, O'Donnell PV; Blood and Marrow Transplant Clinical Trials Network. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011 Jul 14;118(2):282-8. doi: 10.1182/blood-2011-03-344853. Epub 2011 Apr 28.</citation>
    <PMID>21527516</PMID>
  </results_reference>
  <results_reference>
    <citation>Eapen M, O'Donnell P, Brunstein CG, Wu J, Barowski K, Mendizabal A, Fuchs EJ. Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transplant. 2014 Oct;20(10):1485-92. doi: 10.1016/j.bbmt.2014.05.015. Epub 2014 May 23. Review.</citation>
    <PMID>24862638</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2009</study_first_submitted>
  <study_first_submitted_qc>February 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2009</study_first_posted>
  <results_first_submitted>May 20, 2015</results_first_submitted>
  <results_first_submitted_qc>August 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 7, 2015</results_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia/Lymphoma</keyword>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>Mantel-Cell Lymphoma</keyword>
  <keyword>Hematopoietic Transplant</keyword>
  <keyword>Haplo-Identical Transplant</keyword>
  <keyword>Non-Myeloablative Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Results will be published in a manuscript</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Haplo-marrow Transplantation</title>
          <description>Haploidentical bone marrow transplantation using a non-myeloablative preparative regimen.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Relapse/Progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Received transplant.</population>
      <group_list>
        <group group_id="B1">
          <title>Haplo-marrow Transplantation</title>
          <description>Haploidentical bone marrow transplantation using a non-myeloablative preparative regimen.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.4" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance-status score</title>
          <description>Assesses patient self-perceived global quality of life and functioning (excellent, very good, good, fair, poor), where 100 equals perfect quality of life.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>100%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Disease</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Acute Lymphoblastic Leukemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Myelogeneous Leukemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biphenotypic/Undifferentiated Leukemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hodgkins Lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Large Cell Lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marginal Zone B-cell Lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mantle Cell Lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Human leucocyte antigen (HLA) Typing Match Score - GVH direction</title>
          <description>HLA typing will be performed at high resolution (allele level) for the HLA-A, -B, Cw, DRB1, and –DQB1 loci. A minimum match of 5/10 is required.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>5/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HLA Typing Match Score - Host vs Graft (HVG) direction</title>
          <description>HLA typing will be performed at high resolution (allele level) for the HLA-A, -B, Cw, DRB1, and –DQB1 loci. A minimum match of 5/10 is required.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>5/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10/10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78" lower_limit="21" upper_limit="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival at 180 Days From the Time of Transplant</title>
        <time_frame>Measured at Month 6 and Year 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haplo-marrow Transplantation</title>
            <description>Haploidentical bone marrow transplantation using a non-myeloablative preparative regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival at 180 Days From the Time of Transplant</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.7" lower_limit="70.0" upper_limit="91.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0" lower_limit="44.1" upper_limit="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutrophil Recovery</title>
        <description>Cumulative incidence of neutrophil recovery &gt;500/μL at day +56</description>
        <time_frame>Measured at Days 28, 56, 90, and 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haplo-marrow Transplantation</title>
            <description>Haploidentical bone marrow transplantation using a non-myeloablative preparative regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Neutrophil Recovery</title>
          <description>Cumulative incidence of neutrophil recovery &gt;500/μL at day +56</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="89.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="89.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="96.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="96.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Graft Failure</title>
        <description>Primary graft failure is defined as &lt; 5% donor chimerism on all measurements.</description>
        <time_frame>Measured at Day 67</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haplo-marrow Transplantation</title>
            <description>Haploidentical bone marrow transplantation using a non-myeloablative preparative regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Graft Failure</title>
          <description>Primary graft failure is defined as &lt; 5% donor chimerism on all measurements.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Graft Failure</title>
        <description>Secondary graft failure is defined as initial recovery followed by neutropenia with &lt; 5% donor chimerism. If no chimerism assays were performed and absolute neutrophil count is &lt; 500/mm3, then it will be counted as a secondary graft failure.</description>
        <time_frame>Measured at Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haplo-marrow Transplantation</title>
            <description>Haploidentical bone marrow transplantation using a non-myeloablative preparative regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Graft Failure</title>
          <description>Secondary graft failure is defined as initial recovery followed by neutropenia with &lt; 5% donor chimerism. If no chimerism assays were performed and absolute neutrophil count is &lt; 500/mm3, then it will be counted as a secondary graft failure.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Recovery</title>
        <description>Platelet Recovery to 20K</description>
        <time_frame>Measured at Days 56, 90, and 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haplo-marrow Transplantation</title>
            <description>Haploidentical bone marrow transplantation using a non-myeloablative preparative regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Recovery</title>
          <description>Platelet Recovery to 20K</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" lower_limit="93.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Recovery</title>
        <description>Platelet Recovery to 50K</description>
        <time_frame>Measured at Days 56, 90, and 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haplo-marrow Transplantation</title>
            <description>Haploidentical bone marrow transplantation using a non-myeloablative preparative regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Recovery</title>
          <description>Platelet Recovery to 50K</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0" lower_limit="63.8" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0" lower_limit="63.8" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0" lower_limit="63.8" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donor Cell Engraftment</title>
        <description>Marrow or Blood Sample. Donor cell engraftment is defined as donor chimerism ≥ 5% on Day ≥ 56 after transplantation. Chimerism should be evaluated on Days ~28, ~56, ~180, and ~365 after transplantation. Chimerism may be evaluated in whole blood or mononuclear fraction.</description>
        <time_frame>Measured at Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haplo-marrow Transplantation</title>
            <description>Haploidentical bone marrow transplantation using a non-myeloablative preparative regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Cell Engraftment</title>
          <description>Marrow or Blood Sample. Donor cell engraftment is defined as donor chimerism ≥ 5% on Day ≥ 56 after transplantation. Chimerism should be evaluated on Days ~28, ~56, ~180, and ~365 after transplantation. Chimerism may be evaluated in whole blood or mononuclear fraction.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chimerism Performed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Donor Percentage ≥95%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Donor Percentage 5%-95%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Donor Percentage &lt;5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Graft-versus-host Disease (GVHD)</title>
        <time_frame>Measured at Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haplo-marrow Transplantation</title>
            <description>Haploidentical bone marrow transplantation using a non-myeloablative preparative regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Graft-versus-host Disease (GVHD)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade II-IV Acute GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" lower_limit="18.9" upper_limit="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade III-IV Acute GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic GVHD</title>
        <time_frame>Measured at Year 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haplo-marrow Transplantation</title>
            <description>Haploidentical bone marrow transplantation using a non-myeloablative preparative regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic GVHD</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="2.9" upper_limit="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Progression-free survival is defined as the minimum time interval of the times to relapse/recurrence, to death or to last follow-up.</description>
        <time_frame>Measured at Year 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haplo-marrow Transplantation</title>
            <description>Haploidentical bone marrow transplantation using a non-myeloablative preparative regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Progression-free survival is defined as the minimum time interval of the times to relapse/recurrence, to death or to last follow-up.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" lower_limit="32.0" upper_limit="62.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-related Mortality (TRM)</title>
        <time_frame>Measured at 6 months and 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haplo-marrow Transplantation</title>
            <description>Haploidentical bone marrow transplantation using a non-myeloablative preparative regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-related Mortality (TRM)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="0.0" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="0.0" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infections</title>
        <description>Number of infections; infections will be reported by anatomic site, date of onset, organism and resolution, if any. Patients will be followed for infection for 1 year post-transplant.</description>
        <time_frame>Measured at Year 1</time_frame>
        <population>36 patients incurred a total number of 108 infection events.</population>
        <group_list>
          <group group_id="O1">
            <title>Haplo-marrow Transplantation</title>
            <description>Haploidentical bone marrow transplantation using a non-myeloablative preparative regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Infections</title>
          <description>Number of infections; infections will be reported by anatomic site, date of onset, organism and resolution, if any. Patients will be followed for infection for 1 year post-transplant.</description>
          <population>36 patients incurred a total number of 108 infection events.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-10 Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1-year post-transplant</time_frame>
      <desc>Serious adverse events are defined as events associated with death, life-threatening event, disability, congenital anomaly, required intervention to prevent permanent impairment or damage, hospitalization or other serious adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Haplo-marrow Transplantation</title>
          <description>Haploidentical bone marrow transplantation using a non-myeloablative preparative regimen.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.92</frequency_threshold>
        <default_vocab>MedDRA v12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Mendizabal</name_or_title>
      <organization>The EMMES Corporation</organization>
      <phone>301-251-1161</phone>
      <email>amendizabal@EMMES.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

